替普瑞酮治疗慢性酒精相关性胃炎92例疗效分析

Clinical efficacy of teprenone on 92 patients with ethanol-induced chronic gastritis

目的探讨替普瑞酮对慢性酒精相关性胃炎临床转归的影响。方法选择在内镜下诊断的与酒精有确切关联的慢性胃炎患者92例,分为三组:幽门螺杆菌阳性替普瑞酮治疗组(A组);幽门螺杆菌阴性替普瑞酮治疗组(B组);幽门螺杆菌阴性硫糖铝治疗组(C组)。于治疗后进行临床症状评分,通过胃镜检查选取病理标本进行胃黏膜损伤指数、超氧化物歧化酶(SOD)、过氧化氢酶(CAT)、胃黏膜激活的胞外信号调节激酶(ERK)1/2表达的比较,并记录三组患者不良反应发生的情况。结果与C组比较,治疗后A、B组的临床症状明显改善(P均<0.05)。治疗后A、B组的胃黏膜损伤指数、CAT水平及激活的ERK1/2蛋白表达较C组均有统计学意义(P均<0.05),而SOD水平及不良反应发生率的比较差异无统计学意义(P均>0.05)。结论替普瑞酮能够显著改善酒精引发的胃炎患者的临床症状及组织病理情况,值得在临床进一步推广。

Objective To investigate the clinical efficacy of teprenone in the treatment of ethanol-induced chronic gastritis. Methods A total of 92 patients with ethanol-induced chronic gastritis diagnosed by endoscopic examination were divided into 3 groups： 30 patients with infection of Helicobacter pylori （Hp） received teprenone （group A）, 31 patients with no infection of Hp received teprenone （group B） and 31 patients with no infection of Hp were given sueralfate （group C）. The clinical symptoms were evaluated. The samples of gastric mucosa were obtained after therapy to calculate the ulcer index and examine the levels of superoxide dismutase （SOD）, catalase （CAT） and the expression of activated extracellular signal regulated kinase 1/2 （ERK 1/2）, and the incidence of adverse reactions were recorded and compared. Results After therapy, the clinical symptoms in groups A and B were much better than that in group C （all P 〈 0.05）. The ulcer index, the level of CAT and the expression of activated ERK 1/2 in groups A and B were all significantly different as compared to those in group C （all P〈 0.05）, while no difference was noted in the level of SOD and the incidence of adverse reactions （all P 〉 0,05）. Conclusion Teprenone can relieve the clinical symptoms and pathological condition.